for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arcturus Therapeutics Holdings Inc

ARCT.O

Latest Trade

48.22USD

Change

0.36(+0.75%)

Volume

428,299

Today's Range

46.88

 - 

48.33

52 Week Range

8.51

 - 

63.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

Arcturus Therapeutics begins human trials of potential COVID-19 vaccine

Arcturus Therapeutics Holdings Inc said on Tuesday the first group of participants had been dosed in an early-stage trial testing its COVID-19 vaccine candidate and that results from the trial were expected in the fourth quarter.

BRIEF-Arcturus Therapeutics To Be Added To Russell 2000® Index

* ARCTURUS THERAPEUTICS TO BE ADDED TO RUSSELL 2000® INDEX Source text for Eikon: Further company coverage:

Singapore scientists to start human trials of COVID-19 vaccine in August

Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics <ARCT.O> plan to start human trials in August after promising initial responses in mice.

BRIEF-Arcturus Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Study Of ARCT-810

* ARCTURUS THERAPEUTICS ANNOUNCES FIRST HEALTHY VOLUNTEER DOSED IN PHASE 1 STUDY OF ARCT-810 FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY Source text for Eikon: Further company coverage:

CORRECTED-BRIEF-Arcturus Reports Positive Preclinical Data For Covid-19 Vaccine Candidate (April 27)

(Corrects company name in second bullet) Arcturus Therapeutics Holdings Inc:

BRIEF-Arcturus Therapeutics Announces Proposed Public Offering Of Common Stock

* ARCTURUS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Arcturus Therapeutics Plans To Initiate A Human Clinical Trial This Summer For Its Covid-19 Vaccine

* ARCTURUS THERAPEUTICS ANNOUNCES CLINICAL TRIAL TIMELINE FOR ITS COVID-19 VACCINE

BRIEF-Arcturus Therapeutics Files Prospectus Supplement To Offer And Sell Up To $40 Million Of Common Stock - SEC Filing

* ARCTURUS THERAPEUTICS FILES PROSPECTUS SUPPLEMENT TO OFFER AND SELL UP TO $40 MILLION OF COMMON STOCK - SEC FILING Source : (https://bit.ly/2QMTMVq) Further company coverage:

BRIEF-Arcturus Therapeutics Reports Fourth Quarter And Year End 2019 Financial Results

* ARCTURUS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS

BRIEF-Arcturus Awarded S$14 MLN In Grants To Support Development Of Covid-19 Vaccine By Singapore Economic Development Board

* AWARDED S$14 MILLION (ABOUT US$10 MILLION) IN GRANTS TO SUPPORT DEVELOPMENT OF COVID-19 VACCINE BY SINGAPORE ECONOMIC DEVELOPMENT BOARD Source text for Eikon: (bit.ly/2TnTrKI) Further company coverage:

BRIEF-Arcturus Therapeutics And Duke-Nus Medical School Partner To Develop A Coronavirus Vaccine Using Starr Technology

* ARCTURUS THERAPEUTICS AND DUKE-NUS MEDICAL SCHOOL PARTNER TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE USING STARR TECHNOLOGY™ Source text for Eikon: Further company coverage:

BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics

* AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING

BRIEF-Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne

* JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE

BRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates

* ARCTURUS THERAPEUTICS FILES LAWSUIT AGAINST JOSEPH E. PAYNE AND HIS ASSOCIATES FOR VIOLATIONS OF FEDERAL SECURITIES LAWS

BRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGM

* JOSEPH E. PAYNE -ON APRIL 18, SENT LETTER TO ARCTURUS THERAPEUTICS LTD. BOARD TO RESTATE HIS PRIOR DEMAND TO CONVENE EGM OF SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2F05p2z) Further company coverage:

BRIEF-Joseph Payne Says Calling On Arcturus Therapeutics' Board To Hold EGM "Without Further Delay"

* JOSEPH PAYNE SAYS CALLING ON ARCTURUS THERAPEUTICS' BOARD TO HOLD ITS EXTRAORDINARY GENERAL MEETING "WITHOUT FURTHER DELAY"

BRIEF-‍Arcturus Therapeutics Initiates Lawsuit Against Former CEO Joseph Payne

* ARCTURUS THERAPEUTICS INITIATES LAWSUIT AGAINST FORMER PRESIDENT AND CEO JOSEPH PAYNE

BRIEF-Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders

* ARCTURUS THERAPEUTICS - CO SOUGHT TO APPOINT NEW INDEPENDENT AUDITOR IN ORDER TO REPORT FINANCIAL RESULTS, INCLUDING ITS FINANCIAL STATEMENTS FOR 2017

BRIEF-Arcturus Therapeutics Comments On Amended 13D Filing

* ARCTURUS THERAPEUTICS LTD - COMMENTED ON AMENDED 13D FILING BY JOSEPH E. PAYNE

BRIEF-Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics

* JOSEPH PAYNE SAYS EMAILED LETTER DATED FEBRUARY 12, REQUESTED BOARD OF ARCTURUS THERAPEUTICS CONVENE EXTRAORDINARY GENERAL MEETING AS SOON AS POSSIBLE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up